- Home
- NBIX
as 11-07-2025 2:19pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 14.4B | IPO Year: | 1996 |
| Target Price: | $172.06 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.19 | EPS Growth: | 12.44 |
| 52 Week Low/High: | $84.23 - $157.67 | Next Earning Date: | 10-28-2025 |
| Revenue: | $2,682,700,000 | Revenue Growth: | 19.61% |
| Revenue Growth (this year): | 23.68% | Revenue Growth (next year): | 18.02% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RASTETTER WILLIAM H | NBIX | Director | Nov 5 '25 | Sell | $151.82 | 18,000 | $2,732,689.80 | 40,360 | |
| Gano Kyle | NBIX | Chief Executive Officer | Nov 4 '25 | Sell | $141.97 | 300 | $42,591.00 | 140,407 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
8 days ago
Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.
GuruFocus.com
8 days ago
Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ...
BioPharma Dive
8 days ago
Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win
Simply Wall St.
8 days ago
Neurocrine Biosciences (NBIX): Net Margin Miss Challenges Bullish Earnings Growth Narratives
Simply Wall St.
9 days ago
Neurocrine Biosciences (NBIX): Evaluating Valuation After Q3 Earnings Beat and Pipeline Progress
Investor's Business Daily
9 days ago
Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat
MT Newswires
9 days ago
Wedbush Raises Price Target on Neurocrine Biosciences to $149 From $143, Keeps Outperform Rating
MT Newswires
9 days ago
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.